A Clear Scope
We focus our investments on clinical-stage companies that are pursuing both traditional small-molecule compounds and innovative modalities, such as bacteriophages and antibody treatments.
How We Invest
The AMR Action Fund makes equity investments in small and mid-size biotech companies that are developing antimicrobial therapeutics for WHO and CDC priority pathogens.
An Expert SAB
Our Scientific Advisory Board (SAB) members are recognized around the world as leading experts across pertinent disciplines, including antibiotic development, clinical trial design, and pharmaceutical manufacturing, ensuring the highest level of diligence for potential investments.
A Global Presence
We build syndicates with financial partners around the world and lead or co-lead several investments each year into promising antimicrobial companies. We leverage our relationships with industry LPs to create value in portfolio companies and set up successful exits.
Advancing New
Antimicrobials to Patients
.png?width=2000&name=final_biomx_logo-01%20(3).png){kind=logo}
.png?width=5334&height=1446&name=final_biomx_logo-01%20(3).png){kind=logo}
Venatorx Pharmaceuticals, located in Malvern, Pennsylvania, is a clinical-stage company focused on discovering and developing novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. The company’s lead asset is a broad-spectrum beta-lactam / beta-lactamase inhibitor that is being developed for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia.
Headquartered in Cambridge, Massachusetts, Vedanta Biosciences is pioneering the rational design of drugs based on defined consortia of commensal bacteria. Vedanta’s lead candidate, VE303, is in development for the prevention of recurrent Clostridioides difficile infection, which the U.S. Centers for Disease Control and Prevention has classified as an “urgent threat.”
Pattern Bioscience, headquartered in Austin, Texas, is an innovative biotechnology developing a diagnostics platform to rapidly identify bacterial pathogens and determine their antibiotic susceptibility. The company’s novel technology is based on single-cell analysis of microorganisms combined with machine learning tools. Current standard-of-care cultures can take up to four days to provide a definitive diagnosis for critically ill patients. Pattern’s aim is to develop a platform that can deliver accurate results in a matter of hours.
-1.png?width=598&height=247&name=utility_therapeutics_logo_RGB%20(1)-1.png){kind=logo}
.png?width=598&height=247&name=utility_therapeutics_logo_RGB%20(1).png){kind=logo}
Utility therapeutics was an AMR Action Fund portfolio company that in April 2024 obtained U.S. FDA approval for pivmecillinam for the treatment of urinary tract infections (UTIs). It marked the first time in 20 years that the FDA approved a new treatment for UTIs. In July 2025, Alembic Pharmaceuticals acquired Utility.
.png?width=1080&height=1080&name=WebsiteBlog%20Images%20(58).png)
Advancing New
Antimicrobials to Patients
If you would like to introduce your company to the AMR Action Fund investment team, please fill out the form below: